open access

Vol 68, No 3 (2018)
Review articles
Get Citation

Progress in adjuvant treatment of melanoma patients

Piotr Rutkowski, Wojciech M. Wysocki, Tomasz Świtaj, Arkadiusz Jeziorski
Nowotwory. Journal of Oncology 2018;68(3):140-145.

open access

Vol 68, No 3 (2018)
Review articles

Abstract

Surgery is therapy of choice in melanoma patients. However, prognosis of patients at stage IIC–IV even after radical resection is very heterogenous and related to high risk of disease relapse. Positive results of clinical trials indicate that in the nearest future systemic adjuvant therapy in high risk melanomas will become the standard of care. New treatment modalities, both molecular targeted therapy with BRAF+MEK inhibitors dabrafenib with trametinib and immunotherapy anti-PD-1 with nivolumab or pembrolizumab have been approved in US and EU.

Abstract

Surgery is therapy of choice in melanoma patients. However, prognosis of patients at stage IIC–IV even after radical resection is very heterogenous and related to high risk of disease relapse. Positive results of clinical trials indicate that in the nearest future systemic adjuvant therapy in high risk melanomas will become the standard of care. New treatment modalities, both molecular targeted therapy with BRAF+MEK inhibitors dabrafenib with trametinib and immunotherapy anti-PD-1 with nivolumab or pembrolizumab have been approved in US and EU.

Get Citation

Keywords

melanoma, adjuvant therapy, BRAF, MEK inhibitors, immunotherapy, anti-PD-1

About this article
Title

Progress in adjuvant treatment of melanoma patients

Journal

Nowotwory. Journal of Oncology

Issue

Vol 68, No 3 (2018)

Pages

140-145

Bibliographic record

Nowotwory. Journal of Oncology 2018;68(3):140-145.

Keywords

melanoma
adjuvant therapy
BRAF
MEK inhibitors
immunotherapy
anti-PD-1

Authors

Piotr Rutkowski
Wojciech M. Wysocki
Tomasz Świtaj
Arkadiusz Jeziorski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Nowotwory. Journal of Oncology dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl